News release details. Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as Vice President of Sales. Mar 02, 2026 Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform. SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager(TM) Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. She has held roles of increasing responsibility at proteomics companies including Olink Proteomics, SomaLogic, and Waters Corporation. "We are pleased to bring on Amber as our first sales hire to take on a major role in introducing the Nautilus Voyager(TM) Platform to the market," said Sujal Patel, Co-Founder and Chief Executive Officer of Nautilus. "She is a proven, mission-driven commercial leader who is ideally suited to accelerate broad adoption of next-generation omics technologies like our Voyager Platform." Ms. Faust's appointment follows two significant milestones for Nautilus as the company advances towards commercialization: the recent debut of the Voyager Platform and launch of the Iterative Mapping Early Access Program. She will guide the company's work to initiate commercial launch of Voyager in late 2026, including securing pre-orders, managing instrument installations at customer sites, and growing market reach. The Nautilus Tau Proteoforms assay is the company's first offering and is already in active use at the Buck Institute for Research on Aging, where researchers are mapping up to 768 distinct tau proteoform groups to further novel biological understanding of neurodegenerative diseases. "Having worked in the proteomics space for nearly two decades, I have seen the field wrestle with the same fundamental limitations, and what Nautilus is doing at the single-molecule level is a genuine step change," said Ms. Faust, Vice President of Sales at Nautilus. "I'm excited to help scale Nautilus' commercial progress by connecting researchers in pursuit of greater proteomics coverage, detail, and resolution with a platform that can meaningfully expand what's possible in drug development and beyond." Ms. Faust holds a Master of Science in Biomedical Science with a concentration in Immunology and Virology from Hood College and a Bachelor of Science in Biology and Chemistry from Lock Haven University. About the Nautilus Voyager(TM) Platform The Voyager Platform employs Nautilus' proprietary Iterative Mapping approach, which is designed to enable rapid measurement of intact single-molecule proteins and proteoforms. The platform's flow cells are designed to accommodate up to 10 billion intact protein molecules, enabling measurement across an exceptionally wide dynamic range. Iterative Mapping independently probes single protein molecules across tens to hundreds of cycles, recording unique binding patterns for each individual molecule. Machine learning algorithms then convert the resulting probe-binding patterns into confident protein and proteoform identifications. Once analysis is complete, single-molecule counts are made available for download and further visualization. The Voyager instrument is designed for operational simplicity and standard lab benchtop placement, with a guided touchscreen user interface and minimal facility requirements, without need for bespoke gas or fluidic connections. About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create Voyager, a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations with respect to the potential of its platform technology, its future products, their functionality and performance or their applicability in biological research and in potentially enabling new diagnostics and therapies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if its development efforts are successful, its product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, Nautilus Biotechnology Inc. may experience material delays as a result of unanticipated events; Nautilus Biotechnology Inc. cannot provide any guarantee or assurance with respect to the outcome of its development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in its Annual Report on Form 10-K filed for the year ended December 31, 2025 and its other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing its views as of any date subsequent to the date of this press release. Disclosure Information Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

News release details. Nautilus Biotechnology to participate in the TD Cowen 46th Annual Health Care Conference. Feb 19, 2026 SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference. Nautilus' management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio. Media Contact [email protected] Investor Contact [email protected]

$1.6m collaboration to advance Parkinson's proteomics research. A $1.6 million research effort is set to advance single-molecule proteomics research in Parkinson's disease (PD). Life sciences company Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar (WCM-Q) and The Michael J Fox Foundation (MJFF) to study the connection between the alpha-synuclein (aSyn) protein and PD. The project will combine WCM-Q's lab expertise in the molecular and chemical biology of neurodegeneration with Nautilus' platform for measuring proteins and their functional variants, called proteoforms, at single-molecule resolution. Understanding the many forms and modifications of alpha-synuclein is a key priority for MJFF, as these differences could improve understanding of PD biology and variability across individuals. The foundation has pledged a $1.6 million research grant to fund the research. "We are proud to receive a research grant from The Michael J Fox Foundation for Parkinson's Research and partner with the collaborative teams at MJFF and the Lashuel lab at Weill Cornell Medicine-Qatar to shed light on the underlying role of alpha-synuclein in Parkinson's disease and to support efforts to advance biomarker research in Parkinson's disease," said Parag Mallick, Co-Founder and Chief Scientist of Nautilus. "This collaboration is further indication of the next-generation sensitivity, dynamic range, reproducibility, and versatility that our proteomics technology brings to neurodegenerative research and beyond." Research on aSyn could be key to tackling PD. The work at MJFF, using discovery and biomarker research efforts, aims to to better characterise alpha-synuclein proteoforms and related pathways. It is hoped this could generatie insights that can inform future clinical research. Studies suggest the protein aSyn may be a critical driver of PD pathogenesis and that post-translational modifications (PTMs) of the protein, including truncation and phosphorylation, could serve as possible drivers of pathogenesis and biomarkers for diagnosis. However, current proteomics approaches are limited in their ability to measure specific proteoforms of aSyn and how those proteoforms impact disease progression. To address this gap, collaborators at Nautilus, WCM-Q, and MJFF aim to develop a single-molecule assay to measure a large panel of aSyn proteoforms, thereby enabling new approaches to early detection, disease stratification, and disease monitoring for PD and related synucleinopathies. "Deciphering alpha-synuclein proteoforms at the single-molecule level holds tremendous promise for advancing Parkinson's disease diagnostics and therapies," added Dr Hilal A Lashuel, Professor of Neuroscience at WCM-Q and a recognised research leader in aSyn. "We are looking forward to working jointly with Nautilus and MJFF to realise this potential by developing innovative assays and technologies that will enable precise mapping of the post-translational modification signatures of alpha-synuclein in health and neurodegenerative disease."